13 Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area

14 Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru

15 Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis

16 Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience

17 First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus

18 Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience

19 First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus

20 Immunization with a Synthetic Helicobacter pylori Peptide Induces Secretory IgA Antibodies and Protects Mice against Infection

21 Increase in antibiotic resistant Helicobacter pylori in a University Hospital in Japan

22 Genetic basis for metronidazole and clarithromycin resistance in Helicobacter pylori strains isolated from patients with gastroduodenal disorders

23 Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance

24 Genotyping and antibiotic resistance properties of Helicobacter pylori strains isolated from human and animal gastric biopsies

25 Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication

26 Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area

27 Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru

28 Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis

29 The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

30 Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor

31 [Level of Helicobacter pylori infection of the gastric mucosa in the optimization of a daily dose of antihelicobacter drugs].

32 Chemical Constituents of Cymbocarpum erythraeum (DC.) Boiss., and Evaluation of Its Anti-Helicobacter pylori Activity

33 Anti-Helicobacter, Antitubercular and Cytotoxic Activities of Scalaranes from the Red Sea Sponge Hyrtios erectus

34 Evidence of the gastroprotective and anti-Helicobacter pylori activities of β-mangostin isolated from Cratoxylum arborescens (vahl) blume

35 Anti-Helicobacter pylori and antiulcerogenic activity of Aframomum pruinosum seeds on indomethacin-induced gastric ulcer in rats

36 Synthesis and biological activity of 5-nitrofuran-containing (1,3,4-thiadiazol-2-yl)piperazine moieties as a new type of anti-Helicobacter pylori heterocycles

37 POTENTIAL IN VITRO ANTI-HELICOBACTER ACTIVITY OF BACTERIOCIN AND BACTERIOCIN-LIKE COMPOUNDS PRODUCED BY LACTOBACILLI

38 In silico probing exercises, bioactive-conformational and dynamic simulations strategies for designing and promoting selective therapeutics against Helicobacter pylori strains.

39 Efficacy and safety of eradication therapy for elderly patients with helicobacter pylori infection.

40 Treatment of Helicobacter pylori.

41 Helicobacter pylori, causation, change in natural history, and why helicobacter-positive duodenal ulcers should not be routinely treated

42 Combined effect between WT1 methylation and Helicobacter pylori infection, smoking, and alcohol consumption on the risk of gastric cancer.

43 Clinical features of Helicobacter pylori antibody-positive junior high school students in Nagano Prefecture, Japan.

44 Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan

45 Corrigendum: Helicobacter pylori cagA+ Is Associated with Milder Duodenal Histological Changes in Chilean Celiac Patients

46 Detection of antimicrobial resistance genes of Helicobacter pylori strains to clarithromycin, metronidazole, amoxicillin and tetracycline among Egyptian patients

47 Reverse Hybrid Therapy Achieves a Similar Eradication Rate as Standard Hybrid Therapy for Helicobacter Pylori Infection.

48 Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori

49 Evidence of viable Helicobacter pylori and other bacteria of public health interest associated with free-living amoebae in lettuce samples by next generation sequencing and other molecular techniques

50 Cytokines, cytokine gene polymorphisms and Helicobacter pylori infection: friend or foe?

51 Investigating effect of Helicobacter pylori treatment on improvement of non-alcoholic fatty liver parameters: a randomized trial

52 Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration.

53 Antibody responses to Helicobacter pylori and risk of developing colorectal cancer in a European cohort.

54 Cloning, expression, and purification of HpaA-CagA fusion recombinant protein of Helicobacter pylori in E. coli BL 21 strain

55 Cloning, expression and purification of HpaA recombinant protein of Helicobacter pylori as a vaccine candidate

56 Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis

57 A Randomized Controlled Trial Comparing Sequential with Triple Therapy for Helicobacter pylori in an Aboriginal Community in the Canadian North

58 Active Helicobacter pylori Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients

59 Ulcusheilung durch Helicobacter-pylori-Eradikation: Genügt eine Woche Therapie?

60 Active Helicobacter pylori Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients

61 Outcome of Radiotherapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Refractory to Helicobacter Pylori Eradication Therapy

62 Pharmacoeconomic comparison of Helicobacter pylori eradication regimens

63 Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

64 Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005

65 The Impact of Gastric Juice pH on the Intraluminal Therapy for Helicobacter pylori Infection

66 Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study

67 Genotypic and Phenotypic Resistance to Clarithromycin in Helicobacter pylori Strains

68 Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment of Helicobacter pylori Infection

69 Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis

70 Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

71 Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern Chile

72 Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis

73 Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial

74 Severe Inflammation and Reduced Bacteria Load in Murine Helicobacter Infection Caused by Lack of Phagocyte Oxidase Activity

75 Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey

76 First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens

77 Gastritis from NSAIDS to Helicobacter pylori

78 The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease

79 Molecular Patterns of Resistance Among Helicobacter pylori Strains in South-Western Poland

80 Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005

81 Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study

82 Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori

83 Molecular Patterns of Resistance Among Helicobacter pylori Strains in South-Western Poland

84 Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study

85 Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies

86 antibiotic resistance in helicobacter pylori: a mutational analysis from a tertiary care hospital in kashmir, india

87 epidemiology of helicobacter pylori and caga-positive infections and global variations in gastric cancer

88 cage as a biomarker of the pathogenicity of helicobacter pylori

89 helicobacter pylori seropositivity in patients with hyperemesis gravidarum in lakes region

90 protease activity of helicobacter pylori strains and their association with histopathological changes of the gastric tissue

91 helicobacter pylori genetic diversification in the mongolian gerbil model

92 helicobacter pylori and cardiovascular complications: a mechanism based review on role of helicobacter pylori in cardiovascular diseases

93 influence of intestinal indigenous microbiota on intrafamilial infection by helicobacter pylori in japan

94 implications of antibiotic resistance in the management of helicobacter pylori infection: canadian helicobacter study group

95 population structure of <it>helicobacter pylori </it>among ethnic groups in malaysia: recent acquisition of the bacterium by the malay population

96 prevalence of helicobacter pylori vaca genotypes and caga gene in dental plaque of asymptomatic mexican children

97 caracterización de los pacientes infectados por helicobacter pylori durante un trienio

98 prevalence of helicobacter pylori caga and icea genes and their association with gastrointestinal diseases

99 detouring the undesired route of helicobacter pylori-induced gastric carcinogenesis

100 in vitro incorporation of <i>helicobacter pylori</i> into <i>candida albicans</i> caused by acidic ph stress

101 the synthetic antimicrobial peptide pexiganan and its nanoparticles (pnps) exhibit the anti-helicobacter pylori activity in vitro and in vivo

Keyword Connections

Journals

Research Groups

Bibliographies